These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at their medium- to long-term outlook.” ...

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health.

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings. Coca-Cola on ...

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in ...

The TIME100 Health list, assembled by the American news magazine TIME, highlights global leaders, advocates, and innovators who are transforming healthcare systems and advancing public health.The ...

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core operating income set to grow by low double-digits. View on euronews ...

“We've taken, I think, appropriate actions with inventory levels and in terms of managing our supply chain to enable us to ...